Clinical Implications and Predictive Significance of Combining FNA-Tg and BRAF V600E
Overview
This case study highlights the diagnostic utility of combining fine-needle aspiration thyroglobulin (FNA-Tg) measurement and BRAF V600E mutation analysis in assessing cervical lymph node metastasis from papillary thyroid carcinoma (PTC). The integration of these tests rectified a histopathological misdiagnosis, confirming a rare case of cervical lymph node micrometastasis.
Background
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, with a significant proportion of patients exhibiting cervical lymph node metastasis (LNM). Accurate assessment of LNM is critical for individualized treatment strategies, as misdiagnosis can lead to either overdiagnosis or under-treatment. The combination of FNA-Tg and BRAF V600E testing may enhance diagnostic accuracy in this context.
Data Highlights
No numerical data or trial data provided in the article.
Key Findings
The patient presented with a diagnosis of PTC and initially negative histopathological findings for cervical LNM.
Both FNA-Tg and BRAF V600E tests returned positive results, indicating the presence of metastasis.
A comprehensive re-evaluation of histopathological specimens confirmed cervical lymph node micrometastasis.
Follow-up assessments showed no significant signs of recurrence after intensive TSH suppression therapy.
Clinical Implications
The findings indicate that integrating FNA-Tg and BRAF V600E testing can provide a reliable diagnostic approach for detecting cervical lymph node metastasis in PTC.
Conclusion
The case underscores the importance of combining FNA-Tg and BRAF V600E analysis in the diagnostic process for cervical lymph node metastasis in PTC.
